Liver Transplant Compared With Standard Medical Treatment for Neuroendocrine Tumors Spread to the Liver
Compares liver transplant with usual medicines in adults with neuroendocrine tumors in the liver.
Plain-language title generated from the registry record
Registry title: Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases
Key facts
- Where
- Tianjin, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07913113, who can take part
Where in China
- Tianjin Firsr Central HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chiyi Chen
- Trial code
- NCT07913113
- Record updated
- 3 November 2026
- Original description
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesRead full original descriptionShow less
Liver Transplantation Compared With Conventional Medical Therapy for Well-Differentiated (G1/G2) Gastroenteropancreatic Neuroendocrine Tumors With Unresectable Liver Metastases: A Two-Center, Non-Randomized, Patient-Preference-Based Prospective Cohort Study
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases
Inclusion: Age 18-70 years at enrollment; Histologically confirmed, well-differentiated (G1 or G2) gastroenteropancreatic neuroendocrine tumor (pancreatic or midgut/hindgut primary); Unresectable, liver-dominant metastatic disease (multifocal/bilobar involvement not amenable to curative resection or ablation); Ki-67 proliferation index ≤ 10% at the most recent biopsy, with stable disease for at least 6 months on standard therapy; Primary tumor resected, or resectable/planned for resection as part of the treatment strategy; No uncontrolled extrahepatic metastatic disease; ECOG performance status 0-1; Treatment group assigned by patient/family preference after balanced multidisciplinary counseling; both options (transplantation vs conventional therapy) medically feasible and discussed; Written informed consent.
Exclusion: Uncontrolled extrahepatic metastases or progressive disease despite adequate systemic therapy at enrollment; For candidates considering transplantation: serious comorbidities precluding major surgery, including uncontrolled cardiopulmonary disease, active infection, decompensated cirrhosis with severe portal hypertension, or other contraindications to transplantation and immunosuppression; Other active malignancy within the past 5 years (except adequately treated non-melanoma skin cancer or cervical carcinoma in situ); Poorly differentiated neuroendocrine carcinoma (G3, Ki-67 above threshold) or mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN); Pregnancy or lactation; Inability or unwillingness to comply with protocol follow-up; Participation in another interventional clinical trial with potential interference with endpoints.